In adults, the Oxford/AstraZeneca vaccine had 70%...

In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.

Abstract

SOURCE CITATION: Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99-111. 33306989.

Authors

Chagla Z

Journal

Annals of Internal Medicine, Vol. 174, No. 3,

Publisher

American College of Physicians

Publication Date

March 1, 2021

DOI

10.7326/acpj202103160-029

ISSN

1056-8751

Associated Experts

Zain Chagla

Associate Professor, Faculty of Health Sciences

Visit profile

Labels

In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team